Proximie Partners with U.S. MedTech Leader Imperative Care to Advance Robotic Stroke Treatment System

Proximie Partners with U.S. MedTech Leader Imperative Care to Advance Robotic Stroke Treatment System

The leading global health technology platform digitising operating rooms (“OR”), announces a partnership with U.S.-based medical technology company, Imperative Care – with the aim of driving the development of a robotic surgical system to treat ischemic stroke. Imperative Care researches, develops and…

Read MoreProximie Partners with U.S. MedTech Leader Imperative Care to Advance Robotic Stroke Treatment System
Varian Launches IntelliBlate in Europe, Enhancing Image-Guided Cancer Treatment with Integrated Microwave Ablation Technology

Varian Launches IntelliBlate in Europe, Enhancing Image-Guided Cancer Treatment with Integrated Microwave Ablation Technology

Varian, a Siemens Healthineers company, today announced the European launch of IntelliBlate, its next generation microwave ablation solution, for the treatment of soft tissue tumors. Now CE-marked, IntelliBlate represents a pivotal milestone in expanding access to an integrated, intuitive, and…

Read MoreVarian Launches IntelliBlate in Europe, Enhancing Image-Guided Cancer Treatment with Integrated Microwave Ablation Technology
Aviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women's Testosterone Therapy, at ENDO 2025

Aviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women’s Testosterone Therapy, at ENDO 2025

Aviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women’s Testosterone Therapy, at ENDO 2025 Aviva Biopharm Inc. (Aviva Bio), a clinical-stage biopharmaceutical company developing next-generation hormone therapies for women, announced today that new preclinical data on its lead…

Read MoreAviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women’s Testosterone Therapy, at ENDO 2025
ViiV Healthcare Expands Licensing Deal with Medicines Patent Pool to Widen Access to Long-Acting Injectable HIV Therapy

ViiV Healthcare Expands Licensing Deal with Medicines Patent Pool to Widen Access to Long-Acting Injectable HIV Therapy

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include patents relating to its…

Read MoreViiV Healthcare Expands Licensing Deal with Medicines Patent Pool to Widen Access to Long-Acting Injectable HIV Therapy
Simulations Plus Invests in Clinical Development Technology Company Nurocor

Simulations Plus Invests in Clinical Development Technology Company Nurocor

Simulations Plus, a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to…

Read MoreSimulations Plus Invests in Clinical Development Technology Company Nurocor
SBC Medical Group Appoints Renowned Plastic Surgery Expert Dr. Steven R. Cohen as Medical Strategy Advisor to Drive Global Expansion

SBC Medical Group Appoints Renowned Plastic Surgery Expert Dr. Steven R. Cohen as Medical Strategy Advisor to Drive Global Expansion

SBC Medical Group Appoints Renowned Plastic Surgery Expert Dr. Steven R. Cohen as Medical Strategy Advisor to Drive Global Expansion SBC Medical Group Holdings (headquarters: California, USA; CEO: Yoshiyuki Aikawa) is pleased to announce that Dr. Steven R. Cohen, a…

Read MoreSBC Medical Group Appoints Renowned Plastic Surgery Expert Dr. Steven R. Cohen as Medical Strategy Advisor to Drive Global Expansion
AdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia

AdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia

AdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia AdventHealth and Anthem Blue Cross Blue Shield of Georgia (Anthem) are pleased to announce a new multi-year contractual agreement…

Read MoreAdventHealth and Anthem Blue Cross Blue Shield of Georgia Ink Multi-Year Deal to Broaden Access to Quality Care in Northwest Georgia
HistoSonics Secures Expanded Insurance Coverage for Liver Tumor Therapy, Reaching 7 Million Highmark Blue Cross Blue Shield Members

HistoSonics Secures Expanded Insurance Coverage for Liver Tumor Therapy, Reaching 7 Million Highmark Blue Cross Blue Shield Members

HistoSonics , maker of the Edison® Tissue Ablation System , today announced that Highmark Blue Cross Blue Shield has issued four new positive medical policy decisions for the use of Tissue Ablation technology in the treatment of liver tumors. The decisions expand…

Read MoreHistoSonics Secures Expanded Insurance Coverage for Liver Tumor Therapy, Reaching 7 Million Highmark Blue Cross Blue Shield Members
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Process for Personalized RNA Cancer Therapies

Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Process for Personalized RNA Cancer Therapies

Elegen , a leading next-generation DNA manufacturer, and Nutcracker Therapeutics , a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics…

Read MoreElegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Process for Personalized RNA Cancer Therapies
CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment

CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment

CEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment Today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory…

Read MoreCEL-SCI to Partner With Leading Saudi Pharma Firm to Advance Multikine for Head and Neck Cancer Treatment
Elegen and Nutcracker Therapeutics Launch Pilot of First Fully Cell-Free Manufacturing Process for Personalized RNA Cancer Therapies

Elegen and Nutcracker Therapeutics Launch Pilot of First Fully Cell-Free Manufacturing Process for Personalized RNA Cancer Therapies

A global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer…

Read MoreElegen and Nutcracker Therapeutics Launch Pilot of First Fully Cell-Free Manufacturing Process for Personalized RNA Cancer Therapies
Parse Technology-Powered Research Maps Neuronal Pathways, Advancing Neurodegenerative Disease Insights

Parse Technology-Powered Research Maps Neuronal Pathways, Advancing Neurodegenerative Disease Insights

Parse Biosciences, a leading provider of easy-to-use and scalable single-cell sequencing solutions, today announced that a groundbreaking study published in Science used Parse’s single-cell technology to reveal how signaling pathways drive the formation of multiple neuronal subtypes. By linking specific signals to cell fate…

Read MoreParse Technology-Powered Research Maps Neuronal Pathways, Advancing Neurodegenerative Disease Insights